Literature DB >> 10482568

Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

F Kern1, I P Surel, N Faulhaber, C Frömmel, J Schneider-Mergener, C Schönemann, P Reinke, H D Volk.   

Abstract

Cell-mediated immunity plays an essential role in the control of infection with the human cytomegalovirus (HCMV). However, only a few CD8(+)-T-cell epitopes are known, with the majority being contained in the pp65 phosphoprotein, which is believed to dominate the CD8(+)-T-cell response to HCMV. Here, we have readdressed the issue of CD8(+) T cells specific for the 72-kDa major immediate-early protein (IE-1), which is nonstructural but is found very early and throughout the replicative cycle. Using a novel flow-cytometric assay, we were able to identify CD8(+)-T-cell epitopes (by IE-1 peptide-specific induction of cytokine synthesis) and simultaneously measure the frequency of cells directed against them. For this purpose, 81 pentadecamer peptides covering the complete 491-amino-acid sequence of IE-1 were tested on peripheral blood mononuclear cells of anti-HCMV immunoglobulin G-seropositive donors. At least 10 new epitopes were identified, and the fine specificity and presenting HLA molecule of the first of them was determined. The frequencies of CD8(+) T cells directed against IE-1 were similar to those directed against pp65 in donors tested with known pp65-derived peptides. Importantly, additional testing of a corresponding set of peptides covering the complete sequence of pp65 on 10 of these donors identified individuals whose CD8(+) T cells recognized IE-1 but not pp65 and vice versa, clearly illustrating that either protein may be a major target. In summary, our results suggest that IE-1 is far more important as a CD8(+)-T-cell target than current opinion suggests.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482568      PMCID: PMC112835          DOI: 10.1128/JVI.73.10.8179-8184.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment.

Authors:  J L Craigen; J E Grundy
Journal:  Transplantation       Date:  1996-10-27       Impact factor: 4.939

3.  T-cell epitope mapping by flow cytometry.

Authors:  F Kern; I P Surel; C Brock; B Freistedt; H Radtke; A Scheffold; R Blasczyk; P Reinke; J Schneider-Mergener; A Radbruch; P Walden; H D Volk
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

4.  Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product.

Authors:  M J Gilbert; S R Riddell; B Plachter; P D Greenberg
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

5.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

Authors:  D J Diamond; J York; J Y Sun; C L Wright; S J Forman
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

6.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

Authors:  M R Wills; A J Carmichael; K Mynard; X Jin; M P Weekes; B Plachter; J G Sissons
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 7.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition?

Authors:  A I Toro; J Ossa
Journal:  Res Virol       Date:  1996 Jul-Aug

Review 9.  Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.

Authors:  S R Riddell; B A Walter; M J Gilbert; P D Greenberg
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

10.  Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins.

Authors:  L J Burns; J C Pooley; D J Walsh; G M Vercellotti; M L Weber; A Kovacs
Journal:  Transplantation       Date:  1999-01-15       Impact factor: 4.939

View more
  88 in total

Review 1.  Recent developments in flow cytometry.

Authors:  A Scheffold; F Kern
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

Review 2.  Immunofluorescence analysis of T-cell responses in health and disease.

Authors:  H T Maecker; V C Maino; L J Picker
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein.

Authors:  Virginie Prod'homme; Christelle Retière; Ralitza Valtcheva; Marc Bonneville; Marie-Martine Hallet
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.

Authors:  Naeem Khan; Mark Cobbold; Joanne Cummerson; Paul A H Moss
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

Review 7.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

8.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

9.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

10.  HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Authors:  Aude G Chapuis; Corey Casper; Steve Kuntz; Jia Zhu; Annelie Tjernlund; Kurt Diem; Cameron J Turtle; Melinda L Cigal; Roxanne Velez; Stanley Riddell; Lawrence Corey; Philip D Greenberg
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.